Publications by authors named "P Smisek"
Brucellosis is a zoonosis with non-specific clinical symptoms involving multiple systems and organs. Its prevalence is low in most of EU countries, which can lead to the difficulties in laboratory and clinical diagnostic. Due to its relationship to the Ochrobactrum spp.
View Article and Find Full Text PDFFour Additional Doses of PEG-L-Asparaginase During the Consolidation Phase in the AIEOP-BFM ALL 2009 Protocol Do Not Improve Outcome and Increase Toxicity in High-Risk ALL: Results of a Randomized Study.
J Clin Oncol
March 2024
Purpose: The AIEOP-BFM ALL 2009 protocol included, at the end of the induction phase, a randomized study of patients with high-risk (HR) ALL to investigate if an intensive exposure to pegylated L-asparaginase (PEG-ASNASE, 2,500 IU/sqm once a week × 4) on top of BFM consolidation phase IB allowed us to decrease minimal residual disease (MRD) and improve outcome.
Patients And Methods: A total of 1,097 patients presented, from June 2010 to February 2017, with one or more of the following HR criteria: rearrangement, hypodiploidy, prednisone poor response, poor bone marrow response at day 15 (Flow MRD ≥10%), or no complete remission (CR) at the end of induction. Of them, 809 (85.
Article Synopsis
- High levels of antibodies against polyethylene glycol (anti-PEG antibodies) can significantly affect how quickly the drug PEG-asparaginase (PEG-ASNase) is cleared from the body, particularly in children with acute lymphoblastic leukemia.
- In a study involving 1444 children, both anti-PEG IgG and IgM antibodies were evaluated, with IgM showing a stronger correlation to increased drug clearance rates.
- The study concluded that pre-existing high levels of anti-PEG antibodies, especially IgM, lead to a more rapid clearance of PEG-ASNase, impacting treatment effectiveness.
Article Synopsis
- Cytogenetic and molecular changes at the time of relapse significantly impact the prognosis of children with de novo acute myeloid leukemia (AML), though their role has been under-studied.
- An international study reviewed data from 403 out of 569 pediatric AML patients to identify the prognostic value of cytogenetic profiles at relapse, finding that certain genetic aberrations correlated with better or worse outcomes.
- The results suggest that assessing cytogenetic profiles at relapse is crucial for determining survival chances and could enhance personalized treatment strategies for young patients with relapsed AML.